Drugs / borage seed oil
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT00806442 | Dec 2008 → Apr 2012 | asthma | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 1/2 | NCT00029679 | Sep 2000 → Jul 2005 | asthma | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT01560988 | Feb 2013 → May 2015 | asthma | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01211769 | Feb 2006 → Jun 2008 | alcohol dependence | Federal University of São Paulo | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00072982 Comparator | Nov 2006 → May 2008 | rheumatoid arthritis | National Center for Complementary and Integrative Health (NCCIH) | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | borage seed oil | “4.0 g/day borage seed oil and 7.0 g/day echium seed oil” NCT01560988 ↗ |
| Known as | Borage oil | “Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram” NCT01211769 ↗ |
| Action | Inhibit | “Dietary supplementation with gamma linolenic acid (GLA) in borage seed oil provides effective inhibition of leukotriene generation” NCT00806442 ↗ |